Source: The Financial Express
Access to affordable pneumococcal conjugate vaccine (PCV) will become tougher after the Indian patent office granted a patent to US pharma major Pfizer for its PCV13 product, marketed as Prevnar13.
Access to affordable pneumococcal conjugate vaccine (PCV) will become tougher after the Indian patent office granted a patent to US pharma major Pfizer for its PCV13 product, marketed as Prevnar13. The granting of this patent would block manufacturers in India, including Aurobindo Pharma, Panacea Biotech, BE and Serum Institute, from supplying pneumonia vaccine which protects against 13 types of pneumococcal bacteria. “This is a direct blow to the Indian manufacturers. While we do respect the patent laws, we are mulling legal options, including going to an IPR Tribunal for challenging the patent,” an official from the vaccine industry told FE. Manufacturers will have to find new routes to develop a non-infringing PCV vaccine which may delay the availability of competing products in the pipeline from Indian producers. Pfizer’s patent allows it to continue controlling the PCV market in India until 2026 and blocks developing country vaccine manufacturers from supplying a competing version of Pfizer’s PCV. Pfizer and GlaxoSmithKline (GSK) control a duopoly market for PCV, the world’s best-selling vaccine that has brought in nearly $40 billion in sales between 2009 and Q2 of 2017 for these two pharmaceutical corporations. Pfizer’s PCV13 earnings from 2009 to Q2 2017 is $35.2 billion and GSK’s PCV10 earnings in the same period is $4.5 billion. Continue reading
Pfizer application for patent was met with opposition from Indian vaccine maker Panacea Biotec and Medicines Sans Frontieres (MSF), a Paris-based international humanitarian-aid non-governmental organization on grounds that Pfizer is seek patent for mere addition of serotypes to the already established 7 valent vaccine and does not meet the inventive step requirement.
Indian Patent Office granted patent to Pfizer’s pneumonia vaccine PCV13 marketed as Prevnar13.
The patent granted to Pfizer on August 11 came into the public eye today. It involves the method of conjugating (assembling) together serotypes of streptococcus pneumonia into a single carrier.
The approval comes over a decade after the company applied for the patent in the country. Continue reading
Various groups believe the decision will make the shot less accessible to the poor.
India has granted Mumbai-based pharmaceutical company Pfizer Inc a patent for its pneumonia vaccine Prevenar 13, amid opposition from groups that say the decision will made the shot less accessible for financially-weak patients, Reuters reported on Tuesday. The patent office’s decision prohibits other firms from making affordable versions of the vaccine and gives Pfizer the exclusive rights to sell the shot in India till 2026. Continue reading
Source: Live Mint
India has granted Pfizer a patent for Prevnar 13 pneumonia vaccine, in spite of opposition from the heath group Médecins Sans Frontières (MSF)
New Delhi: India has granted US pharmaceutical company Pfizer Inc. a patent for its pneumonia vaccine Prevnar 13, in spite of opposition from the health group Médecins Sans Frontières (MSF). The non-profit group had filed a “patent opposition” to prevent Pfizer from getting a patent on its pneumococcal conjugate vaccine (PCV 13).
While the approval comes almost a decade after Pfizer subsidiary Wyeth applied for a patent for Prevnar 13, MSF warns that grant of the patent would block other manufacturers in India from supplying the vaccine—it protects against 13 types of pneumococcal bacteria—to those who need it most. Continue reading
MUMBAI, AUGUST 22:
The grant of an Indian patent to Pfizer’s Prevenar13, a pneumococcal conjugate vaccine, has raised the hackles of pro-health group MSF who are worried that it will hamper access to the vaccine.
“It’s unfair and unacceptable that almost a million children die each year from pneumonia, even though a life-saving vaccine is available,” said MSF’s Prince Mathew, adding that the vaccine’s prices were not affordable even to governments. Continue reading
Source: All India Drug Action Network (AIDAN)
The Department of Pharmaceuticals has circulated a Draft Pharmaceutical Policy, 2017 which can be accessed here.
The draft policy identifies the following key objectives:
a. Making essential drugs accessible at affordable prices to the common masses;
b. Providing a longer term stable policy environment for the pharmaceutical sector;
c. Making India sufficiently self-reliant in end to end indigenous drug manufacturing;
d. Ensuring world class quality of drugs for domestic consumption & exports;
e. Creating an environment for R&D to produce innovator drugs